Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Sarcoma 1Head & Neck 1Genitourinary 1Gastrointestinal 1CNS 1Breast 1

Conditions

Tongue Neoplasms 1Salivary Gland Neoplasms 1Rectal Neoplasms 1Pancreatic Neoplasms 1Oropharyngeal Neoplasms 1Nasopharyngeal Neoplasms 1Mouth Neoplasms 1Laryngeal Neoplasms 1Hypopharyngeal Neoplasms 1Gliosarcoma 1Glioblastoma 1Esthesioneuroblastoma, Olfactory 1Colonic Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms, Male 1Breast Neoplasms 1Brain Neoplasms 1

Interventions

Bevacizumab 5pembrolizumab 3Paclitaxel 3fludarabine 2Sorafenib 2Nivolumab 2Gemcitabine 2Cyclophosphamide 2Azacitidine 2vocimagene amiretrorepvec 1ulixertinib 1temsirolimus 1sacituzumab govitecan 1ruxolitinib 1rucaparib 1regorafenib 1pazopanib 1motexafin gadolinium 1erythromycin propionate-N-acetylcysteinate 1durvalumab 1cediranib 1cc-486 1carboxyamido-triazole 1capmatinib 1belzutifan 1aflibercept 1abiraterone 1Thalidomide 1Temozolomide 1Sunitinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Glioblastoma × FPP(RGD)2 × Genitourinary × Clear all
NCT01806675 2019-10-03

18F-FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis Therapy

Stanford University

Phase 1/2 Completed
25 enrolled 14 charts
BreastCNSGastrointestinalGenitourinaryHead & NeckSarcomaThoracic

Brain Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Colonic Neoplasms, Glioblastoma, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Nasopharyngeal Neoplasms, Oropharyngeal Neoplasms, Pancreatic Neoplasms, Rectal Neoplasms, Salivary Gland Neoplasms, Tongue Neoplasms, Esthesioneuroblastoma, Olfactory, Gliosarcoma, Breast Neoplasms, Male

Data powered by HemOnc (CC BY 4.0) Colophon âš¡